These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 18221178)
1. Drug effects on drug targets: inhibition of enzymes by neuroleptics, antimycotics, antibiotics and other drugs on human pathogenic amoebas and their anti-proliferative effects. Ondarza RN Recent Pat Antiinfect Drug Discov; 2007 Nov; 2(3):206-16. PubMed ID: 18221178 [TBL] [Abstract][Full Text] [Related]
2. Drug targets from human pathogenic amoebas: Entamoeba histolytica, Acanthamoeba polyphaga and Naegleria fowleri. Ondarza RN Infect Disord Drug Targets; 2007 Sep; 7(3):266-80. PubMed ID: 17897063 [TBL] [Abstract][Full Text] [Related]
3. The effects by neuroleptics, antimycotics and antibiotics on disulfide reducing enzymes from the human pathogens Acanthamoeba polyphaga and Naegleria fowleri. Ondarza RN; Iturbe A; Hernández E Exp Parasitol; 2007 Jan; 115(1):41-7. PubMed ID: 16806188 [TBL] [Abstract][Full Text] [Related]
4. In vitro antiproliferative effects of neuroleptics, antimycotics and antibiotics on the human pathogens Acanthamoeba polyphaga and Naegleria fowleri. Ondarza RN; Iturbe A; Hernández E Arch Med Res; 2006 Aug; 37(6):723-9. PubMed ID: 16824931 [TBL] [Abstract][Full Text] [Related]
6. Polyamine-trypanothione pathway: an update. Ilari A; Fiorillo A; Genovese I; Colotti G Future Med Chem; 2017 Jan; 9(1):61-77. PubMed ID: 27957878 [TBL] [Abstract][Full Text] [Related]
7. Preparative enzymatic synthesis of trypanothione and trypanothione analogues. Comini MA; Dirdjaja N; Kaschel M; Krauth-Siegel RL Int J Parasitol; 2009 Aug; 39(10):1059-62. PubMed ID: 19477177 [TBL] [Abstract][Full Text] [Related]
8. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Schmidt A; Krauth-Siegel RL Curr Top Med Chem; 2002 Nov; 2(11):1239-59. PubMed ID: 12171583 [TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry characterization of trypanothione and novel peptides of medical importance isolated from Acanthamoeba polyphaga. Ondarza RN; Hernandez E; Hurtado G; Woolery M; Hernandez-Sandoval F Infect Disord Drug Targets; 2013 Apr; 13(2):133-40. PubMed ID: 23808873 [TBL] [Abstract][Full Text] [Related]
10. Targeting trypanothione metabolism in trypanosomatid human parasites. Olin-Sandoval V; Moreno-Sánchez R; Saavedra E Curr Drug Targets; 2010 Dec; 11(12):1614-30. PubMed ID: 20735352 [TBL] [Abstract][Full Text] [Related]
11. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Heby O; Persson L; Rentala M Amino Acids; 2007 Aug; 33(2):359-66. PubMed ID: 17610127 [TBL] [Abstract][Full Text] [Related]
12. Buthionine sulfoximine is a multitarget inhibitor of trypanothione synthesis in Trypanosoma cruzi. Vázquez C; Mejia-Tlachi M; González-Chávez Z; Silva A; Rodríguez-Zavala JS; Moreno-Sánchez R; Saavedra E FEBS Lett; 2017 Dec; 591(23):3881-3894. PubMed ID: 29127710 [TBL] [Abstract][Full Text] [Related]
15. Metabolism and functions of trypanothione in the Kinetoplastida. Fairlamb AH; Cerami A Annu Rev Microbiol; 1992; 46():695-729. PubMed ID: 1444271 [TBL] [Abstract][Full Text] [Related]
16. The parasite-specific trypanothione metabolism of trypanosoma and leishmania. Krauth-Siegel RL; Meiering SK; Schmidt H Biol Chem; 2003 Apr; 384(4):539-49. PubMed ID: 12751784 [TBL] [Abstract][Full Text] [Related]
17. Polyamine metabolism in Leishmania: from arginine to trypanothione. Colotti G; Ilari A Amino Acids; 2011 Feb; 40(2):269-85. PubMed ID: 20512387 [TBL] [Abstract][Full Text] [Related]
20. Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. Augustyns K; Amssoms K; Yamani A; Rajan PK; Haemers A Curr Pharm Des; 2001 Aug; 7(12):1117-41. PubMed ID: 11472257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]